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Ab s t r Ac t
The evolving coronavirus disease (COVID-19) spread across the world, affecting more than 200 countries and territories. The genomic analysis 
proposed that the COVID-19 virus first observed in bats and later spread to humans through unidentified intermediate hosts in the Wuhan 
Seafood Market, China, in December of 2019. COVID-19 belongs to the family of Beta coronavirus and also refers to severe acute respiratory 
syndrome coronavirus 2(SARS-CoV2) due to its genetic similarities with severe acute respiratory syndrome coronavirus (SARS-CoV- pandemic 
observed in 2003).
At present no any promising treatment strategies or vaccine is available. Hence many researchers and physicians are studying existing agents 
for its use against COVID-19 infections. Although it provides only symptomatic relief, it helps to halt infection. 
The intention of this review article is to provide a brief summary of the origin, basic structure, pathogenicity, potent available therapeutic 
strategies against COVID-19 infection.’
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In t r o d u c t I o n
The capricious outbreak coronavirus disease 2019 was first 
recognized in patients with severe respiratory Disease in Wuhan, 
Hubei, China. Earlier research has been called this outbreak as 
pneumonia of unknown etiology.[1] The causative agent was 
identified by testing throat swab of such infected patients led by the 
Chinese Centre for Disease Control and Prevention (CCDC) on Jan 7, 
2020, which later on named by World Health Organization (WHO) 
and International Committee on the taxonomy of Virus (ICTV) as a 
Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV 2) and 
disease as a COVID-19 due to its crown-like structure.[2,3] The name of 
SARS-CoV 2 due it is genetically and structurally resemblances with 
severe acute respiratory syndrome coronavirus[4] From the last two 
decades there are three emerging viruses has been reported form 
the same family of coronavirus that are severe acute respiratory 
syndrome (SARS-CoV), middle east. respiratory syndrome (MERS) 
and recently its SARS CoV2.[11] The first outbreak of SARS-CoVwere 
came in Guangdong province, Southern China, and neighboring 
countries in 2003[5] leads to 813 deaths among 8437 reported cases 
worldwide.[6] Then after nine years, the respiratory syndrome was 
reported in the middle east has been called MERS, which adds 
burdens of a total of 2519 laboratory-confirmed cases, including 
866 associated deaths (case-fatality rate: 34.3%) were reported 
globally.[7,8] and now its SARS-CoV2 affecting the lives of millions. 
Even though most of the countries declared lockdown and national 
emergencies, the infection and severity of pandemic is increasing 
day by day as there is no promising treatment has been found till 
the date. Since its discovery, more than 3 435 894 cases have been 
infected, including nearly 239604 deaths.[9,10]
Coronavirus disease (COVID-19) pandemic is continuously 
spreading across the world very promptly. The mild conditions 
like the common cold and severe circumstances such as severe 
acute respiratory syndrome coronavirus (SARS-CoV)and Middle 
East respiratory syndrome coronavirus (MERS-CoV) are the leading 
problems of coronavirus infection.[11] The worrisome features of 
COVID-19 are its capacity to spread rapidly, and its tendency to 
reason severe disease in geriatric populations and patients with 
existing health disorders. The virus is contagious and transferred 
from one individual to next through sneezing and coughing or 
contact with the secretion of infected persons. COVID-19 disease is 
more severe in the elderly and persons with other chronic diseases 
such as chronic respiratory disease, diabetes, cardiovascular disease, 
hypertension, and renal injury). The COVID-19 is characterized by 
symptoms such as dry cough fatigue, fever, and, as well as sputum 
production, headache, etc.[12-14]
At present, no hopeful antiviral regimens or vaccines are 
existing for COVID-19. Some guidelines are issued by the health 
authority of each country and also by the WHO to treat COVID-19 
pandemic. However, the existing treatment protocols are mainly 
based on providing symptomatic relief and upregulation of 
respiratory functions. 
or I g I n, bA s I c st r u c t u r e, A n d 
PAt h o g e n e s I s
Coronaviruses (CoVs) are a large group of viruses common among 
many animals, including Human. They can cause respiratory 
illnesses in humans and gastrointestinal illnesses in animals. Some 
basic information[15] regarding to CoVs are given in Table 1.
©2020 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/
by/4.0/), which permits unrestricted use, distribution, and  reproduction in any medium, provided the original work is properly cited.
Table 1: Origin, basic structure of CoVs
Family-coronaviridae
Subfamily-Nidovirales
Order-Nidovirales
Subgroups-alpha (α), beta (β), gamma (γ) and delta (δ) coronavirus.
Size-65-125nm in diameter
Contains Single-stranded RNA,
crown-like spikes on the outer surface of the virus
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Human have long been infected by coronavirus since from 2003 
outbrek of SARS followed by MERS (2012) and COVID-19. All three 
diseases are contagious, which can be transmitted from person to 
person during coughing, sneezing by the inhalation or ingestion 
of viral droplets, and also when a person comes in contact with 
an infected source.[16] The coronavirus genome is consists of 
30000 nucleotides, which encodes for several proteins such as 
nucleocapsid (N) protein, membrane (M) protein, Spike (S) protein, 
and Envelop (E) protein and several non-structural proteins (nsp) 
as shown in Figure 2. The genetic material is enclosed within the 
enveloped protein of lipid bilayer. The SARS-CoV 2 is a single-
stranded RNA virus that is positioned within capsid protein and 
surrounded by the nucleocapsid protein or N-protein. The single-
stranded RNA material further responsible for the production 
of genomic and subgenomic material by the accomplishment 
of processes like replication and transcription(mediated by the 
N-terminal of nucleocapsid protein/N-protein) and also allows the 
virus to steal human cells and convert them into virus factories. 
The membrane/ M- protein is mostly found at the virus surface 
and maintained the intact structure of the virus. The binding of 
viral spike protein with host cell surface receptors is governed 
by M-protein, which further responsible for the entry of the virus 
in a host cell.[20] The major functions of membrane permeability 
and virus-host cell interaction are carried out by the E-protein.[21]
[Figure 1].
Pathogenesis
Basically, the SARS-CoV2 has a characteristic spike protein, which 
plays a crucial role in binding of virus with host cell surface receptors. 
It has been reported that the spike proteins contain a receptor-
binding domain (RBD). The glutamine residue of this domain forms 
a virus-host receptor complex by binding with lysine residue of 
the human angiotensin-converting enzyme 2 (ACE2) receptors. 
Subsequently, receptor binding leads to the fusion of viral and 
host cell membranes and further releases single-stranded genomic 
RNA into the cytoplasm of the host cell. Then this single-stranded 
RNAundergoes translation and replication to produce polyproteins 
(pp1a and pp1ab), which subsequently cleave into 15–16 nsps. 
Following the translation and replication, negative-sense copies 
of both genomic and subgenomic RNAs are synthesized, which 
serve as templates for the synthesis of positive-sense genomic 
RNA and subgenomic mRNAs. The subgenomic mRNAs act as a 
template for the production of the various structural and several 
other proteins. Then the nucleocapsid is formed by incorporation 
of viral genomic RNA into N protein, which further interacts with 
the endoplasmic reticulum (ER) and transfers to the endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC) where the 
other M, S, E protein is being developed. Finally, new virions are 
covered by the smooth-walled vesicles and then transported 
across the membrane of infected cell by the membrane transport 
mechanism i.e. exocytosis. However due to the burden of viral RNA 
and other Structural proteins in the ER and ERGIC, ultimately cell 
death occurs [Figure 2].[24]
SARS-CoV-2with the help of S protein virus binds to the cellular 
receptor ACE2. After receptor binding, the viral RNAreleases into 
cytoplasm, followed by the replication and translation to form new 
genomic, sub-genomic viral material, other structural and non-
structural proteins. Viral proteins and genome RNA are afterward 
collected into virions in the ER and ERGIC and then transported 
via vesicles and released out of the cell via exocytosis mechanism.
Figure 1: Number of confirmed COVID-19 cases reported in the last seven days by country, territory or area, Apr 28 to May 4**
Source: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2
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ACE2- angiotensin-converting enzyme 2; ER- endoplasmic 
reticulum; ERGIC, ER–Golgi intermediate compartments.
Treatment
Till the date, no any promising and curative treatment available 
against SARS-CoV2 infection. As the outbreak of the covid19 
pandemic is increasing rapidly, leading to more deaths throughout 
the world. Whichever treatment protocols using currently only 
provide symptomatic relief and also the potential curative changes 
from person to person. So it takes more attention to develop novel 
therapeutic management against COVID19, which can control the 
progression of infection and thus subsequently halts symptoms. 
  There is multiple drug candidates are currently used and 
further investigated, currently using treatment protocols are based 
on following principals i) Inhibition of SARS- Cov 2 fusion/entry ii) 
disruption of SARS-CoV 2 replication iii)suppression of excessive 
inflammatory response iv)convalescent plasma treatment v) 
Vaccines.[25] The potential dug candidates currently available to 
treat COVID19 are listed below.[Table 2]
The use of convalescent plasma transfusion could be of great 
value in the current pandemic of corona disease pandemic. The 
immediate use of convalescent plasma provides prompt availability 
of a promising treatment while specific vaccines and treatment are 
evaluated and brought to scale. Convalescent plasma from donors 
who have recovered from COVID19 may be most promising when 
used as prophylaxis or when administered shortly after symptoms 
onset within 14 days.[35] The scientist and physicians across the 
globe continuously working hard to find vaccines against SARS-
CoV-2.
co n c lu s I o n
The COVID-19 pandemic becomes a global threat to affect public 
health systems. The severity of pandemic leading to an increasing 
number of cases and deaths day by day. Although WHO other 
health authorities of world and every countries prescribed several 
guidelines to deal with this pandemic and Regardless of knowing 
infectious cycleSARS-CoV-2, there are no promising approaches 
for COVID-19 patients’ treatment. For the last four months, many 
scientists and physicians’ working day and night to find novel 
curative treatments and vaccine against SARS-CoV-2 infection. Most 
of these findings are based on antiviral activities of existing drug 
candidates. So from here now only time will tell us which one of 
these drugs is going to work?
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